Contrastingly, in breast cancer, CCL28 expression has a dual effect: in luminal-like subtypes, it correlates with improved relapse-free survival (RFS) and disease-free survival (DFS), while in triple-negative breast cancer (TNBC), high CCL28 expression is associated with poorer prognosis [62]. Here, CCL28 is linked to triple-negative breast carcinoma.